Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000071
Filing Date
2024-11-12
Accepted
2024-11-12 09:38:06
Documents
7
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 6-K q32024form6-k.htm 6-K 22504
2 EX-99.1 2024 THIRD QUARTER INTERIM FINANCIAL STATEMENT ex991-interimfsseptember30.htm EX-99.1 409935
3 EX-99.2 2024 THIRD QUARTER MD&A ex992-q32024mda.htm EX-99.2 253745
4 EX-99.3 Q3 2024 CERTIFICATION CEO ex993-q32024certificationx.htm EX-99.3 14367
5 EX-99.4 Q3 2024 CERTIFICATION CFO ex994-q32024certificationx.htm EX-99.4 14292
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
7 pipeline.jpg GRAPHIC 517346
  Complete submission text file 0001129928-24-000071.txt   1867581
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 241444289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)